Unhealthy marketing of pharmaceutical products: An international public health concern
(2016) In Journal of Public Health Policy 37(2). p.149-159- Abstract
- I consider the current state of pharmaceutical marketing vis-à-vis ethical and legal standards and advocate measures to improve it. There is abundant evidence of unethical or illicit marketing. It fuels growing concerns about undue corporate influence over pharmaceutical research, education, and consumption. The most extensive evidence of industry transgressions comes from the United States (US), where whistle-blowers are encouraged by financial rewards to help uncover illicit marketing and fraud. Outside the US increasing evidence of transgressions exists. Recently we have observed a range of new measures to align pharmaceutical marketing practices with ethical and legal standards. In the interest of public health, I highlight the need... (More)
- I consider the current state of pharmaceutical marketing vis-à-vis ethical and legal standards and advocate measures to improve it. There is abundant evidence of unethical or illicit marketing. It fuels growing concerns about undue corporate influence over pharmaceutical research, education, and consumption. The most extensive evidence of industry transgressions comes from the United States (US), where whistle-blowers are encouraged by financial rewards to help uncover illicit marketing and fraud. Outside the US increasing evidence of transgressions exists. Recently we have observed a range of new measures to align pharmaceutical marketing practices with ethical and legal standards. In the interest of public health, I highlight the need for additional and more profound reforms to ensure that information about medicines supports quality and resource-efficient care. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/8601255
- author
- Mulinari, Shai LU
- organization
- publishing date
- 2016-02-25
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Journal of Public Health Policy
- volume
- 37
- issue
- 2
- pages
- 149 - 159
- publisher
- Palgrave Macmillan
- external identifiers
-
- pmid:26911654
- pmid:26911654
- scopus:84978780339
- wos:000375140800005
- ISSN
- 0197-5897
- DOI
- 10.1057/jphp.2016.6
- project
- The dilemma of the swine flu vaccine
- language
- English
- LU publication?
- yes
- id
- 65300c30-756b-4a31-8ca9-2b9c3e52a661 (old id 8601255)
- date added to LUP
- 2016-04-01 11:14:41
- date last changed
- 2024-01-22 09:03:12
@article{65300c30-756b-4a31-8ca9-2b9c3e52a661,
abstract = {{I consider the current state of pharmaceutical marketing vis-à-vis ethical and legal standards and advocate measures to improve it. There is abundant evidence of unethical or illicit marketing. It fuels growing concerns about undue corporate influence over pharmaceutical research, education, and consumption. The most extensive evidence of industry transgressions comes from the United States (US), where whistle-blowers are encouraged by financial rewards to help uncover illicit marketing and fraud. Outside the US increasing evidence of transgressions exists. Recently we have observed a range of new measures to align pharmaceutical marketing practices with ethical and legal standards. In the interest of public health, I highlight the need for additional and more profound reforms to ensure that information about medicines supports quality and resource-efficient care.}},
author = {{Mulinari, Shai}},
issn = {{0197-5897}},
language = {{eng}},
month = {{02}},
number = {{2}},
pages = {{149--159}},
publisher = {{Palgrave Macmillan}},
series = {{Journal of Public Health Policy}},
title = {{Unhealthy marketing of pharmaceutical products: An international public health concern}},
url = {{http://dx.doi.org/10.1057/jphp.2016.6}},
doi = {{10.1057/jphp.2016.6}},
volume = {{37}},
year = {{2016}},
}